Resistance patterns and prevalence of the aminoglycoside modifying enzymes in clinical isolates of gram negative pathogens

Global Journal of Pharmacology

Volumn 8, Issue 1, 2014, Pages 73-79

  Chaudhary, Manu ^a   Payasi, Anurag ^a  

^a Venus Medicine Research Centre   (India)

Author keywords

Aminoglycoside Modifying Enzymes; Potentox; Resistance; Susceptibility

Indexed keywords

AMIKACIN; BACTERIAL ENZYME; CEFEPIME; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN AAC(6); PROTEIN ANT(2); PROTEIN APH(3); TOBRAMYCIN; UNCLASSIFIED DRUG;

AAC(6) GENE; ACINETOBACTER; ANT(2) GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APH(3) GENE; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; ESCHERICHIA COLI; KLEBSIELLA; NONHUMAN; POLYMERASE CHAIN REACTION; PSEUDOMONAS;

EID: 84893110718     PISSN: 19920075     EISSN: None     Source Type: Journal    
DOI: 10.5829/idosi.gjp.2014.8.1.8270     Document Type: Article

References (34)

1. Shakil, S., R. Khan, R. Zarrilli and A.U. Khan, 2008. Aminoglycosides versus bacteria-a description of the action, resistance mechanism, and nosocomial battleground. J. Biomed. Sci., 15: 5-14.
2. Gad, G.F., H.A. Mohamed and H.M. Ashour, 2011. Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt. PLoS ONE, 6: e17224.
3. Wang, Y., U. Ha, L. Zeng and S. Jin, 2003. Regulation of membrane permeability by a Two-component regulatory system in Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 47: 95-101.
4. Galimand, M., P. Courvalin and T. Lambert, 2012. RmtF, a new member of the aminoglycoside resistance 16S rRNA N7 G1405 methyltransferase family. Antimicrob. AgentsChemother.,56:3960-3962.
5. Davies, J. and G. Wright, 1997. Bacterial Resistance to Aminoglycoside Antibiotics. Trends in Microbiol., 5: 234-39.
6. Doi, Y. and Y. Arakawa, 2007. 16S Ribosomal RNA Methylation: Emerging Resistance Mechanism against Aminoglycosides. Clin. Infect. Dis., 45: 88-94.
7. Poole, K., 2004. Efflux-mediated multi resistance in Gram-negative bacteria. Clin. Microbiol. Infect., 10: 12-26.
8. Mao, W., M.S. Warren, A. Lee, A. Mistry and O. Lomovskaya, 2001. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 45: 2001-2007.
9. Kim, S.L., J.Y. Jeong, J.B. Jun, S.H. Choi, S.O. Lee, M.N. Kim, J.H. Woo and Y.S. Kim, 2009. Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea. Antimicrob. Agents Chemother., 53: 2643-2645.
10. Miró, E., F. Grünbaum, L. Gómez, A. Rivera, B. Mirelis, P. Coll and F. Navarro, 2013. Characterization of aminoglycoside-modifying enzymes in enterobacteriaceae clinical strains and characterization of the plasmids implicated in their diffusion. Microb. Drug Res., 19: 94-99.
11. Aghazadeh, A., M.A. Rezaee, M.R. Nahaei, R. Mahdian, O. Pajand, F. Saffari, M. Hassan and Z. Hojabri, 2013. Dissemination of aminoglycosidemodifying enzymes and 16S rRNA methylases among Aci77netobacter baumannii and Pseudomonas aeruginosa isolates. Microbial. Drug Resistance., 19: 282-288.
12. Shaw, K.J., P.N. Rather, R.S. Hare and G.H. Miller, 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev., 57: 138-163.
13. th ed. Oxford: Butterworth Heinemann, pp: 452-457.
14. Randhawa, V.S., L. Kapoor, V Singh and G. Mehta, 2004. Aminoglycoside resistance in Enterococci isolated from pediatric septicaemia in a tertiary care hospital in North India. Indian J. Med. Res., 119: 77-79.
15. Shahid, M. And A. Malik, 2005. Resistance due to aminoglycoside modifying enzymes in Pseudomonas aeruginosa isolates from burns patients. Indian J. Med. Res., 122: 324-32.
16. Ubukata, K., N. Yamashita, A. Gotoh and M. Konno, 1984. Purification and characterization of aminoglycoside-modifying enzymes from Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother, 25: 754-9.
17. Matsumara, M., T. Katakura, T. Imanaka and S. Aiba, 1984. Enzymatic and nucleotide sequence studies of a kanamycin-inactivating enzyme encoded by a plasmid from thermophilic bacilli in comparison with that encoded by plasmid pUB110. J. Bacteriol., 160: 413-20.
18. Paulsen, I.T., N. Firth and R.A. Skurray, 1997. Resistance to antimicrobial agents other than betalactams. In The Staphylococci in human disease, Eds., Crossley K.B. and G.L. Archer, Churchill Livingstone, New York Publishers, pp: 175-212.
19. Hughes, W.T., D. Armstrong, G.P. Bodey, A.E. Brown, J.E. Edwards, R. Feld, P. Pizzo, K.V. Rolston, J.L. Shenep and L.S. Young, 1997. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin. Infect. Dis., 25: 551-73.
20. Sanz, M.A., J. Lopez, J.J. Lahuetra, M. Rovira, M. Batlle, C. Perez, L. Vazquez, A. Julia, J. Palau, M. Gutierrez, F.J. Capote, F. Ramos, L. Benlloch, L. Larrea and I. Jarque, Spanish PETHEMA group, 2002. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J. Antimicrob. Chemother., 50: 79-88.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. CLSI document M100-S23. 2013, Wayne, PA 19087 USA.
22. Sambrook, J. and D.W. Russell, 2001. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press.
23. Miller, G.H., F.J. Sabatelli, R.S. Hare, Y. Glupczynski, P. Mackey, D. Shlaes, K. Shimizu and K.J. Shaw, 1997. The most frequent aminoglycoside resistance mechanisms changes with time and geographic area: a reflection of aminoglycoside usage patterns. Clin. Infect. Dis., 24: S46-62.
24. th, November, 2010.
25. Moniri, R., R.K. Farahani, G.H Shajari, M.H.N. Shirazi and A. Ghasemi, 2010. Molecular epidemiology of aminoglycosides resistance in Acinetobacter Spp. with emergence of multidrug-resistant strains. Iranian J. Publ. Health., 39: 63-68.
26. Schmitz, F.J., J. Verhoef and A.C. Fliut, 1999. Prevalence of aminoglycosides resistance in 20 European university hospitals participating in the European SENTRY antimicrobial surveillance programme. Eur. J. Clin. Microbiol. Infect. Dis., 18: 414-421.
27. Vaziri, F., S.N. Peerayeh, Q.B. Nejad and A. Farhadian, 2011. The prevalence of aminoglycosidemodifying enzyme genes (aac (69)-I, aac (69)-II, ant (20)-I, aph (39)-VI) in Pseudomonas aeruginosa. CLINICS, 66: 1519-1522.
28. Padmasini, E., R. Padmaraj and R. Srivani, 2013. High level aminoglycoside resistance and distribution of aminoglycoside resistant genes among clinical isolates of Enterococcus species in Chennai, India, The Scientific World Journal (In Press).
29. Over, U., D. Gur, S. Unal, and G.H. Miller, 2001. The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms. Clin. Microbiol. Infect., 7: 470-8.
30. Estahbanati, H., P. Kashani and F. Ghanaatpisheh, 2002. Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics. Burns, 28: 340-8.
31. Chaudhary, M., S.M. Shrivastava, S. Saurabh and V.K. Dwivedi, 2008. In vitro antimicrobial activity of cefepime, amikacin and their fixed dose combination against some pathogenic bacteria. J. Ecophysiol. Occupational Health, 8: 161-165.
32. Chaudhary, M., S. Kumar and A. Payasi, 2013. Characterization of quinolone resistant genes and control of qnrB transfer by Potentox in clinical isolates. J. Phar. Res., 7: 62-69.
33. Chaudhary, M., A. Payasi and V.K. Dwivedi, 2011. Comparative safety evaluation of potentox® vs co-administration of cefepime and amikacin in healthy albino rat. Int. J. Drug Dev. Res., 3: 348-355.
34. Dwivedi, V.K., M. Chaudhary, A. Soni and S.M. Shrivastava, 2009. Nephrotoxicity reduction by fixed dose combination of cephalosporins and aminoglycosides in mus musculus mice. Asian J. Biochem., 4: 13-21.